|
- IRMS - Nicolae Testemitanu SUMPh
- 1. COLECȚIA INSTITUȚIONALĂ
- MedEspera: International Medical Congress for Students and Young Doctors
- MedEspera 2020
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/11765
Title: | Adverse effects of opioid analgesics during treatment of chronic pain |
Authors: | Ceinac, Ana |
Keywords: | Opioid analgesic;chronic pain;adverse effects |
Issue Date: | 2020 |
Publisher: | MedEspera |
Citation: | CEINAC, Ana. Adverse effects of opioid analgesics during treatment of chronic pain. In: MedEspera: the 8th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2020, p. 279. |
Abstract: | Introduction. Maintaining quality of life is an important parameter during treatment. Pain is
defined as an emotional, unpleasant experience, associated with present or potential tissue
lesion. Pain can be part of having cancer or can be due to cancer treatment and chronic pain
may cause exacerbations. Chronic pain is caused often by late stage cancer and to reduce its
intensity opioids are administered. Therefore, an understanding of the pharmacology of opioids
are required for their safe and appropriate use. Long-term opioid pharmacotherapy is associated
with many adverse effects.Aim of the study.1. Identifying patients using opioid analgesic; 2. Patients observation during
the entire period of treatment; 3. Adverse effects detection, timing when adverse reaction
occurs and measures to be taken to avoid specific adverse reactions.
Materials and methods. After inclusion and exclusion criteria were applied, 100 patients from
Public Medical Sanitary Institution Institute of Oncology from Chisinau were selected for the
study. Patients were randomized in two groups: first group (n=63 ) -patients receiving opioid
analgesic during 14-35 days. Second group (n=37) –patients receiving opioids less then 14
days. Patients were administered following drugs: trimeperidine (promedol) 2% -1ml,
omnopon 1% -1ml, morphine 1% - 1ml and tramadol 5% -2ml. The study period was 02.2018
- 02.2019, clinical effects were assessed by clinical examination and questionnaire. The data
have been analyzed statistically using SPSS software.
Results. Patients, receiving opioids from the first group experienced: constipation (89%),
fatigue (60%), dyspepsia (16%), pruritus (8%), opioid withdrawal syndrome (agitation,
tremors, insomnia, exacerbation of pain, neurovegetative symptoms) - 4%, and psychosis (2%).
Patients from second group presented following side effects: constipation (12%), fatigue
(7%).Early medication was initiated in order to prevent or to reduce adverse effects. Laxatives
were administered for constipation, magnesium hydroxide was used if constipation was
persistent. The dose of drug was reduced to decrease fatigue and drug was administered more
frequently, lowering peak plasma-concentration. Also opioid drug changing was applied or
non-opioid analgesics was included, in order to allow opioid dose reduction. Antiemetics have
been administered to prevent or treat sensation of nausea and vomiting. Antihistamines was
prescribed for pruritus. Doses have been reduced gradually to prevent opioid withdrawal.
Antipsychotics have been administered in psychosis.
Conclusions. Chronic pain can be managed and opioids adverse effects must be anticipated
and treated. |
URI: | https://medespera.asr.md/wp-content/uploads/ABSTRACT-BOOK.pdf http://repository.usmf.md/handle/20.500.12710/11765 |
Appears in Collections: | MedEspera 2020
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|